Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;36(10):3281-3282.
doi: 10.1007/s00467-021-05203-8. Epub 2021 Jul 17.

Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab

Rasmus Ehren  1 , Sandra Habbig  2
Affiliations

Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab

Rasmus Ehren et al. Pediatr Nephrol. 2021 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Rasmus Ehren has no conflict of interest. Sandra Habbig has received honoraria for lecturing from Sanofi-Aventis Deutschland GmbH and honoraria for participation on Advisory Boards of Alexion Pharma GmbH and Greenovation Biotech GmbH.

References

    1. Tanaka K, Adams B, Aris AM, Fujita N, Ogawa M, Ortiz S, Vallee M, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatr Nephrol. 2021;36:889–898. doi: 10.1007/s00467-020-04774-2. - DOI - PMC - PubMed
    1. Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA, 312 Study Group The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2021;100:225–237. doi: 10.1016/j.kint.2020.10.046. - DOI - PubMed
    1. Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H, 311 Study Group The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2020;97:1287–1296. doi: 10.1016/j.kint.2020.01.035. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources